Trials of antihypertensive treatment - New agenda for the millennium

American Journal of Hypertension

Volumn 13, Issue 1 II SUPPL., 2000, Pages

  Julius, Stevo ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Hypertension Optimal Treatment (HOT); Multiple Risk Factor Intervention Trial (MRFIT); Stage I hypertension; Trial of Preventing Hypertension (TROPHY)

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; PRIORITY JOURNAL; REVIEW;

EID: 0033973939     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(99)00251-4     Document Type: Review

References (39)

1. Veterans Administration Cooperative Study on Antihypertensive Agents: A double blind control study of antihypertensive agents. I. Comparative effectiveness of reserpine, reserpine and hydralazine, and three ganglionic blocking agents, chlorisondamine, mecamyamine, and pentolinium tartrate. Arch Intern Med 1960; 106:81-96.
2. Veterans Administration Cooperative Study on Antihypertensive Agents: Double blind control study of antihypertensive agents. II. Further report on the comparative effectiveness of reserpine, reserpine and hydralazine, and three ganglion blocking agents, chlorisondamine, mecamylamine, and pentolinium tartrate. Arch Intern Med 1962;110:222-229.
3. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressure averaging 115 through 120 mm Hg. JAMA 1967;202:1028-1034.
4. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970;213:1143-1152.
5. Medical Research Council Working Party: MRC trial of treatment of mild hypertension: principal results. Br Med J 1985;291:97-104.
6. Australian National Blood Pressure Study: The Australian therapeutic trial in mild hypertension. Lancet 1980; 1:1261-1267.
7. Hypertension Detection and Follow-up Program Cooperative Group: Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979;242:2562-2571.
8. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). JAMA 1991;265:3255-3264.
9. MRC Working Party: Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992;304:405-412.
10. Agodoa L: African American study of kidney disease and hypertension (AASK) - clinical trial update. Ethn Dis 1998;8:249-253.
11. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S, for the HOT Study Group: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-1762.
12. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, Brown C, Rocella EJ: Trends in the prevalence, awareness, treatment and control of hypertension in the adult U.S. population. Data from the health examination Surveys, 1960 to 1961. Hypertension 1995; 26:60-69.
13. Calhoun HM, Dong W, Poulter NR: Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens 1998;16:747-752.
14. Gyarfas I: Control of hypertension in the population. Strategies in affluent and developing countries. Clin Exp Hypertens 1996;18:387-397.
15. Chamontin B, Poggi L, Lang T, Menard J, Chevalier H, Gallois H, Cremier O: Prevalence, treatment, and control of hypertension in the French population. Data from a survey on high blood pressure in general practice, 1994. Am J Hypertens 1998;11:759-762.
16. Faulhaber H-D, Luft FC: Treatment of high blood pressure in Germany. Am J Hypertens 1998;11:750-753.
17. Chockalingham A, Fodor JG: Treatment of raised blood pressure in the population. The Canadian experience. Am J Hypertens 1998;11:747-749.
18. Avanzini F, Alli C, Columbo P, Corsetti A, Columbo F, Tognoni G: Control of hypertension in Italy: results of the Study on Antihypertensive Treatment in General Practice (STAP). Physicians taking part in STAP. G Ital Cardiol 1998;28:760-766.
19. Banegas JR, Rodriguez-Artalejo F, de la Cruz Troca JJ, Guallar-Castillon P, del Rey Calero J: Blood pressure in Spain: distribution, awareness, control, and benefits of a reduction in average pressure. Hypertension 1998;32: 998-1002.
20. Cruickshank JM, Thorp JM, Zacharias FJ: Benefits and potential harm of lowering high blood pressure. Lancet 1987;1:581-584.
21. Wiklund I, Halling K, Ryden-Bergsten T, Fletcher A: Does lowering the blood pressure improve mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) study. Blood Press 1997;6:324-325.
22. Williams RR, Hunt SC, Hopkins PN, Stults BM, Wu LL, Hasstedt SJ, Barlow GK, Stephenson SH, Lalouel JM, Kuida H: Familial dyslipidemic hypertension. JAMA 1988;259:3579-3586.
23. Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, Shitrit A, Fuchs Z: Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest 1985;75:809-817.
24. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Buhler FR: Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972;286:441-449.
25. Palatini P, Julius S: Heart rate and the cardiovascular risk. J Hypertens 1997;15:1-15.
26. Smith SD, Julius S, Jamerson K, Amerena J, Schork N: Hematocrit levels and physiologic factors in relationship to cardiovascular risk in Tecumseh, Michigan. Hypertension 1994;12:455-462.
27. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH: Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reduction in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-838.
28. Hypertension Detection and Follow-up Program Cooperative Group: The effect of treatment on mortality in mild hypertension: results of the Hypertension Detection and Follow-up Program. N Engl J Med 1982;307: 976-980.
29. Stamler J, Stamler R, Neaton JD: Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993;153:598-615.
30. Whelton PK, Buring J, Borhaini NO, Cohen JD, Cook N, Cutler JA, Kiley JE, Kuller LH, Satterfield S, Sacks FM: Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, Phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med 1997;157:2666-2667.
31. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N: A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997;336: 1117-1124.
32. Hypertension Prevention Trial Research Group: The hypertension prevention trial: three-year effects of dietary changes on blood pressure. Arch Intern Med 1990;150:153-162.
33. Folkow B: Physiological aspects of primary hypertension. Physiol Rev 1982;62:347-503.
34. Esler M, Julius S, Zweifler A, Randall O, Harburg E, Gardiner H, DeQuattro V: Mild high-renin essential hypertension: neurogenic human hypertension? N Engl J Med 1977;296:405-411.
35. Naftilan AJ, Pratt RE, Dzau VJ: Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1419-1424.
36. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AJ, Carere RG, Wargovich TJ, Mudra H, Luscher TF, Kubaner MI, Haber HE, Uprichard AC, Pepine CJ, Pitt B: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND study. Circulation 1996;3:258-265.
37. Schiffrin EL, Deng LY: Comparison of effects of angiotensin I-converting enzyme inhibition and beta-blockade for two years function of small arteries from hypertensive patients. Hypertension 1995;25: 699-703.
38. Harrap SB, Van der Merwe WM, Griffin SA, Macpherson F, Lever AF: Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long term. Hypertension 1990;16:603-614.
39. Wu JN, Berecek KH: Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captopril. Hypertension 1993;22:139-146.